- Sporos Bioventures, TX-based company formed to catalyze the development of therapies that target novel disease mechanisms in cancer and immune diseases, closed a $38.1m Series A financing
- The company also plans to use the proceeds to support the development of lead assets across its portfolio and build out the team
- Sporos identifies novel disease mechanisms and strategically deploys talent, capital and access to operational resources to catalyze the development of breakthrough medicines
- Its current pipeline diversified across four entities and includes multiple clinical-stage candidates that investigated for the treatment of multiple indications in cancer and immune disease
- Sporos Director Alex Cranberg, an entrepreneur and business leader with strong ties to the Texas and Houston biotech ecosystem through his time on the University of Texas Board of Regents
- In parallel to the Series A, Michael Wyzga, M.B.A., former chief financial officer of Genzyme, also joins the team as Founding CFO
